19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
Martin-Luther-University of Halle-Wittenberg
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies.
Shanghai Institute of Materia Medica
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
Repare Therapeutics, Inc.
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Hubei Polytechnic University
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Bayer
Synthetic Lethality through the Lens of Medicinal Chemistry.
Istituto Italiano Di Tecnologia
1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
Chong Kun Dang Pharmaceutical
2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS
Bristol-Myers Squibb
Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine
Kronos Bio
Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors
Leo Pharma
Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents
Zenji Research Laboratories
Sulfur-containing compounds targeting vesicular acetylcholine transporter
Washington University